Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis

Pulmonary alveolar proteinosis (PAP) is associated with defective macrophage clearance of surfactant. Here, the authors show that patients with PAP have altered cholesterol-to-phospholipid ratio in their surfactant, and that more importantly, statin therapy and reduction of cholesterol accumulation...

Full description

Bibliographic Details
Main Authors:	Cormac McCarthy, Elinor Lee, James P. Bridges, Anthony Sallese, Takuji Suzuki, Jason C. Woods, Brian J. Bartholmai, Tisha Wang, Claudia Chalk, Brenna C. Carey, Paritha Arumugam, Kenjiro Shima, Elizabeth J. Tarling, Bruce C. Trapnell
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-08-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-018-05491-z

id	doaj-d8cc338509bd449f91fc403c8ee500b8
record_format	Article
spelling	doaj-d8cc338509bd449f91fc403c8ee500b82021-05-11T10:06:37ZengNature Publishing GroupNature Communications2041-17232018-08-01911910.1038/s41467-018-05491-zStatin as a novel pharmacotherapy of pulmonary alveolar proteinosisCormac McCarthy0Elinor Lee1James P. Bridges2Anthony Sallese3Takuji Suzuki4Jason C. Woods5Brian J. Bartholmai6Tisha Wang7Claudia Chalk8Brenna C. Carey9Paritha Arumugam10Kenjiro Shima11Elizabeth J. Tarling12Bruce C. Trapnell13Translational Pulmonary Science Center, Children’s Hospital Medical CenterDivision of Pulmonary and Critical Care Medicine, University of California Los AngelesDivision of Pulmonary Biology, Children’s Hospital Medical CenterTranslational Pulmonary Science Center, Children’s Hospital Medical CenterTranslational Pulmonary Science Center, Children’s Hospital Medical CenterDivision of Pulmonary Medicine, Children’s Hospital Medical CenterDepartment of Radiology, Mayo ClinicDivision of Pulmonary and Critical Care Medicine, University of California Los AngelesTranslational Pulmonary Science Center, Children’s Hospital Medical CenterTranslational Pulmonary Science Center, Children’s Hospital Medical CenterTranslational Pulmonary Science Center, Children’s Hospital Medical CenterTranslational Pulmonary Science Center, Children’s Hospital Medical CenterDepartment of Medicine, University of California Los AngelesTranslational Pulmonary Science Center, Children’s Hospital Medical CenterPulmonary alveolar proteinosis (PAP) is associated with defective macrophage clearance of surfactant. Here, the authors show that patients with PAP have altered cholesterol-to-phospholipid ratio in their surfactant, and that more importantly, statin therapy and reduction of cholesterol accumulation in macrophages can ameliorate PAP in both humans and mice.https://doi.org/10.1038/s41467-018-05491-z
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Cormac McCarthy Elinor Lee James P. Bridges Anthony Sallese Takuji Suzuki Jason C. Woods Brian J. Bartholmai Tisha Wang Claudia Chalk Brenna C. Carey Paritha Arumugam Kenjiro Shima Elizabeth J. Tarling Bruce C. Trapnell
spellingShingle	Cormac McCarthy Elinor Lee James P. Bridges Anthony Sallese Takuji Suzuki Jason C. Woods Brian J. Bartholmai Tisha Wang Claudia Chalk Brenna C. Carey Paritha Arumugam Kenjiro Shima Elizabeth J. Tarling Bruce C. Trapnell Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis Nature Communications
author_facet	Cormac McCarthy Elinor Lee James P. Bridges Anthony Sallese Takuji Suzuki Jason C. Woods Brian J. Bartholmai Tisha Wang Claudia Chalk Brenna C. Carey Paritha Arumugam Kenjiro Shima Elizabeth J. Tarling Bruce C. Trapnell
author_sort	Cormac McCarthy
title	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
title_short	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
title_full	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
title_fullStr	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
title_full_unstemmed	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
title_sort	statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2018-08-01
description	Pulmonary alveolar proteinosis (PAP) is associated with defective macrophage clearance of surfactant. Here, the authors show that patients with PAP have altered cholesterol-to-phospholipid ratio in their surfactant, and that more importantly, statin therapy and reduction of cholesterol accumulation in macrophages can ameliorate PAP in both humans and mice.
url	https://doi.org/10.1038/s41467-018-05491-z
work_keys_str_mv	AT cormacmccarthy statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT elinorlee statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT jamespbridges statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT anthonysallese statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT takujisuzuki statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT jasoncwoods statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT brianjbartholmai statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT tishawang statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT claudiachalk statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT brennaccarey statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT parithaarumugam statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT kenjiroshima statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT elizabethjtarling statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis AT brucectrapnell statinasanovelpharmacotherapyofpulmonaryalveolarproteinosis
_version_	1721448773578653696

Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis

Similar Items